A recent study indicates that individuals who discontinue new weight-loss injections like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who end traditional diet and exercise plans.
Findings released in a major health publication shows that while obese people often shed a large proportion of their body weight while on the medication, the weight is regained at an average rate of 0.8 kg per month after stopping.
"Users buying these treatments should be aware of the danger of rapid rebound weight gain when the medication concludes," stated expert Dr. Susan Jebb.
Such speed of regain suggests a reversion to pre-treatment weight within about 18 months.
Comparing Therapies
The study, which examined dozens of studies involving thousands of participants, contrasted the outcomes of these new drugs with conventional dieting.
Researchers emphasize that people who shed pounds through diet and exercise typically see a slower creep back—perhaps 100 grams monthly—post-intervention.
Understanding the Rapid Rebound
Doctors believe the mechanism of the jabs explains the heightened weight return.
These medications imitate a natural hormone called GLP-1, which controls appetite.
"Long-term administration of GLP-1 levels several times higher than normal might result in the body to generate a reduced amount of its own natural hormone, and could reduce sensitivity to its effects," said Dr. Adam Collins, a dietetics expert.
"Stopping of this GLP-1 'fix' leads to hunger is uncontrolled, making excessive eating a significant risk."
An Ongoing Condition?
The NHS advise the jabs for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts say that, considering the likelihood of weight regain, the therapy should be considered long-term.
This view is echoed by pharmaceutical companies, who state that the findings "highlight the long-term character of obesity," akin to managing conditions like high blood pressure.
User Accounts
Users who have stopped the medication explain a sudden return of appetite.
"I experienced a switch activating and you're instantly ravenous," recalled a patient.
The struggle is exacerbated if users have not adopted sustainable dietary or behavioural changes during therapy.
Significant Use
Recent estimates suggest that a significant number of people in the UK have used these injections in the last 12 months, with desire being substantial.
- Adoption is greater among females compared to men.
- The middle-aged age group shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than public health services.
Finally, clinicians caution that while the jabs are potent agents for shedding pounds, they are not a standalone fix and lasting health benefits likely depends on combined behavioural changes.
